Alimera Sciences Participating in Credit Suisse London One-on-One Healthcare
ATLANTA, Feb. 20, 2013
ATLANTA, Feb. 20, 2013 /PRNewswire/ --Alimera Sciences, Inc. (Nasdaq: ALIM)
("Alimera"), a biopharmaceutical company that specializes in the research,
development and commercialization of prescription ophthalmic pharmaceuticals,
today announced that Dan Myers, president and chief executive officer, will
participate in the Credit Suisse London One-on-One Healthcare Conference on
March 5 – 6, 2013 in London, UK.
About Alimera Sciences, Inc.
Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical
company that specializes in the research, development and commercialization of
prescription ophthalmic pharmaceuticals. Presently Alimera is focused on
diseases affecting the back of the eye, or retina. Its primary product,
ILUVIEN, is an intravitreal implant containing fluocinolone acetonide (FAc), a
non-proprietary corticosteroid with demonstrated efficacy in the treatment of
ICR, LLC for Alimera Sciences John Mills+1-310-954-1105
Press spacebar to pause and continue. Press esc to stop.